Johnson & Johnson (NYSE:JNJ) immediately shared particulars on its surgical robotic platform that it says gives unequalled flexibility and management in comparison with the remainder of the market.
The brand new system is designed with six arms to supply extra management and adaptability in surgical procedure, whereas its arms shall be built-in into the working desk. Moreover, the platform has a zero-footprint design to allow affected person entry, enhance house within the working room and enhance workflow.
J&J’s unveiling included a reputation for the brand new platform: Ottava.
In Italian, “Ottava” means to play music an octave larger, in accordance with J&J robotics chief growth officer Dr. Frederic Moll, an Intuitive Surgical co-founder who joined J&J via its acquisition of his Auris Well being in 2019.
“That (an octave higher) is what we mean to enable in medical intervention,” Moll stated throughout a medical system replace presentation immediately.
Robotic-assisted surgical procedure is presently a sizzling space in medtech — with J&J, Medtronic and others searching for to tackle Intuitive Surgical (NSDQ:ISRG), which dominates the house with its da Vinci robots.
J&J believes its creating platform gives greater than every other obtainable system by way of flexibility.
“Currently, there is no robotic system that provides robotic control and coordination across a full breadth of procedures,” Moll stated. “It is my team’s ambition to enable our platform to improve outcomes across a broad range of disease states.”
Moll stated J&J is within the “exciting stage of development” the place the platform is “coming to life.”
The corporate is planning on starting verification and validation processes for Ottava in 2021, adopted by enrollment in medical trials for the system in 2022.
J&J’s digital ecosystem — designed to attach its surgical and robotic platforms — is about to energy Ottava, whereas the corporate has eyes on combining it with the FDA-cleared Monarch robotic surgical platform acquired from Auris Well being to entry and deal with difficult anatomy in a minimally invasive approach.
“We view Ottava as the surgeon’s instrument for orchestrating a new level and elevating the surgical experience,” Moll stated.
In July, J&J determined to not observe a 510(okay) clearance pathway for its then-unnamed deliberate common surgical procedure robotic — with a purpose to start out first-in-human research with the system set for the second half of 2022 throughout its quarterly earnings name on the time.
Earlier than the COVID-19 pandemic struck the U.S., J&J had been planning some form of robotic surgical procedure reveal in May. The medtech large has been engaged on combining applied sciences that got here out of its earlier Verb Surgical collaboration with the Alphabet (NSDQ:GOOGL) life sciences unit Verily — in addition to the $3.four billion buy of Auris Well being and the Monarch platform.
Listed here are some further highlights from J&J’s medical system replace occasion:
Coping throughout COVID-19
“The complete medtech business is affected by this once-in-a-generation disruption with COVID-19, together with us,” stated Ashley McEvoy, the top of J&J’s medical system enterprise. “We believe in the strength of the medtech market in the long-term and expect it to return to growth.”
McEvoy believes that the pandemic has been a catalyst for change and evolution within the medtech house and stated J&J has responded by investing to drive progress, divesting in non-core companies and finishing acquisitions to strengthen in high-growth areas, comparable to digital surgical procedure.
“We are advancing disruptive, transformational innovations,” McEvoy stated. “We are continuously investing in our core while advancing areas with high-growth potential.”
J&J maintains an optimistic outlook for the post-pandemic market, with expectations for double-digit operational gross sales progress in 2021 and a doubled value for its new product pipeline in comparison with 2018.
“We’re well-positioned to get via COVID,” McEvoy stated. “We’re committed to emerging stronger from this pandemic.”
Monarch and digital surgical procedure play
Together with the corporate’s pleasure over the Ottava system, J&J has excessive hopes for its growth within the total digital surgical procedure house.
The Monarch platform is already FDA-cleared for sure indications, however J&J is trying to transfer the platform towards most cancers analysis and therapy. The corporate sees the potential to supply endoluminal drug and power therapy via this avenue.
The worldwide head of J&J’s lung most cancers initiative Dr. Avi Spira stated that the localized drug supply, straight to cancerous or pre-cancerous lesions, gives minimized toxicity, elevated efficacy and the potential for brand new therapies.
J&J has plans to start out first-in-human trials for the Monarch in delivering drug and power therapy.
“We believe our unified, unique approach will ultimately expand beyond lung cancer,” Spira stated. “There’s an opportunity for J&J to further transform the trajectory of human health.”